EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of HSK39297 in Chinese Healthy Subjects: A Phase 1 Clinical Trial

Yuyang Dai iD, Feng Wu iD, Siyang Ni iD, Xiaojun Hu iD, Ying Han iD, Ying Jiao iD, Huan Lu iD, Yilin Liu iD, Lingling Wang iD, Yunfei Lin iD, Meixia Chen iD, Chao Wang iD und 3 weitere

Clinical and Translational Science · 2025

DOI: 10.1111/cts.70281 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Yuyang Dai und 14 weiteren Autor:innen. Beteiligte Einrichtung: National Institute for Drug Clinical Trial, Beijing Tongren Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Complement Inactivating Agents. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

HSK39297 is a novel complement factor B inhibitor, and this phase 1 trial was designed to assess its pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability in healthy Chinese subjects. This study included 46 subjects in the single ascending dose (SAD) part (50–600 mg) and 50 subjects in the multiple ascending dose (MAD) part (50–125 mg BID and 200–300 mg QD). Among them, a food effect study was conducted in the SAD 200 mg group. Adverse events (AEs) reported after the initial dose of the study drug were considered treatment‐emergent AEs (TEAEs). Blood samples were collected to measure plasma concentrations of HSK39297 at predefined time points and analyzed at a centralized laboratory. In addition, PD analysis was conducted by measuring complement alternative pathway (AP) activity and Bb concentrations. According to the results, we found single and multiple doses of HSK39297 were safe and well tolerated in all subjects. Within SAD of 50–600 mg dose range, the C max , AUC 0‐ t , and AUC 0‐∞ exhibited nonlinear PK characteristics. The high‐fat meals did not significantly affect the absorption rate and systemic exposure levels of HSK39297, and GMRs for fed versus fasting states were 108.05% (99.66%, 117.15%), 98.73% (89.34%, 109.09%), and 97.86% (84.66%, 113.11%), respectively. In MAD part, dose‐drug exposure showed a linear relationship. PD analysis indicated that oral administration of HSK39297 tablets resulted in dose‐dependent inhibition of the AP activity and Bb concentration. These findings support advancing HSK39297 into later‐phase trials for complement‐mediated glomerular diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Complement Inactivating AgentsHumansMaleAdultFemaleYoung AdultHealthy VolunteersDose-Response Relationship, DrugArea Under CurveMiddle AgedFood-Drug InteractionsAdministration, OralAsian PeopleChina

Stichwörter der Autor:innen

complement factor B inhibitorcomplement systemglomerular diseasespharmacodynamicspharmacokineticssafety

Substanzen

Complement Inactivating Agents

Autor:innen und Institutionen

  • National Institute for Drug Clinical Trial, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
  • Haisco Pharmaceutical Group Co., Ltd., Chengdu, Sichuan Province, China.

ORCID-Profile: Yuyang Dai, Feng Wu, Siyang Ni, Xiaojun Hu, Ying Han, Ying Jiao, Huan Lu, Yilin Liu, Lingling Wang, Yunfei Lin, Meixia Chen, Chao Wang, Qinghe Wu, Fangqiong Li, Laichun Lu

Zitieren

APA

Dai, Y., Wu, F., Ni, S., Hu, X., Han, Y., Jiao, Y., Lu, H., Liu, Y., Wang, L., Lin, Y., Chen, M., Wang, C., Wu, Q., Li, F., & Lu, L. (2025). Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of HSK39297 in Chinese Healthy Subjects: A Phase 1 Clinical Trial. Clinical and Translational Science. https://doi.org/10.1111/cts.70281

Vancouver

Dai Y, Wu F, Ni S, Hu X, Han Y, Jiao Y, et al. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of HSK39297 in Chinese Healthy Subjects: A Phase 1 Clinical Trial. Clinical and Translational Science. 2025. doi:10.1111/cts.70281

BibTeX
@article{Dai2025,
  author = {Dai, Yuyang and Wu, Feng and Ni, Siyang and Hu, Xiaojun and Han, Ying and Jiao, Ying and Lu, Huan and Liu, Yilin and Wang, Lingling and Lin, Yunfei and Chen, Meixia and Wang, Chao and Wu, Qinghe and Li, Fangqiong and Lu, Laichun},
  title = {Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of HSK39297 in Chinese Healthy Subjects: A Phase 1 Clinical Trial},
  journal = {Clinical and Translational Science},
  year = {2025},
  doi = {10.1111/cts.70281}
}
Kostenlos starten →